Page last updated: 2024-11-03

probenecid and Urinary Lithiasis

probenecid has been researched along with Urinary Lithiasis in 1 studies

Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Stamp, L1
Dalbeth, N1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effects of Allopurinol on Inflammatory Markers and Morphostructural Changes Evidenced by Musculoskeletal Ultrasound in Individuals With Asymptomatic Hyperuricemia. A Proof of Concept[NCT04012294]Phase 3200 participants (Anticipated)Interventional2019-08-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for probenecid and Urinary Lithiasis

ArticleYear
Urate-lowering therapy for asymptomatic hyperuricaemia: A need for caution.
    Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4

    Topics: Allopurinol; Asymptomatic Diseases; Drug Eruptions; Drug Hypersensitivity; Febuxostat; Gout Suppress

2017